Literature DB >> 3564050

Cisplatin nephrotoxicity: role of filtration and tubular transport of cisplatin in isolated perfused kidneys.

K Miura, R S Goldstein, D A Pasino, J B Hook.   

Abstract

Isolated perfused rat kidneys were used to determine the contribution of filtration and tubular transport of cisplatin to its nephrotoxicity. Perfusion of kidneys with 0.5 mM cisplatin concomitantly reduced tubular reabsorption of electrolytes and glomerular filtration rate in a time-dependent manner. These renal functional changes were similar to those obtained following in vivo cisplatin treatment (10 mg/kg). In vitro exposure to cisplatin reduced the renal clearance of organic ions without reducing renal perfusate flow, suggesting that renal hemodynamic changes do not mediate cisplatin-induced proximal tubular dysfunction. Inhibition of organic ion transport also was observed in non-filtering perfused kidneys treated with 0.5 mM cisplatin, implying that filtration of cisplatin is not a prerequisite for induction of toxicity. These data also suggest that cisplatin transport from a basolateral site may be important in the development of acute nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3564050     DOI: 10.1016/0300-483x(87)90145-4

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  14 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Acute cisplatin nephrotoxicity in the rat. Evidence for impaired entry of sodium into proximal tubule cells.

Authors:  M J Field; T E Bostrom; F Seow; A Z Györy; D J Cockayne
Journal:  Pflugers Arch       Date:  1989-09       Impact factor: 3.657

Review 3.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

4.  Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity.

Authors:  Keizo Fukushima; Akira Okada; Hiroyuki Oe; Mika Hirasaki; Mami Hamori; Asako Nishimura; Nobuhito Shibata; Nobuyuki Sugioka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

5.  Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.

Authors:  Ryan M Franke; Ashley M Kosloske; Cynthia S Lancaster; Kelly K Filipski; Chaoxin Hu; Oliver Zolk; Ron H Mathijssen; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2010-07-02       Impact factor: 12.531

Review 6.  An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures.

Authors:  George J Dugbartey; Luke J Peppone; Inge A M de Graaf
Journal:  Toxicology       Date:  2016-10-04       Impact factor: 4.221

7.  The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity.

Authors:  Navjotsingh Pabla; Robert F Murphy; Kebin Liu; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-14

8.  Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.

Authors:  Jing Li; Seongho Kim; Xianyi Sha; Richard Wiegand; Jianmei Wu; Patricia LoRusso
Journal:  Clin Cancer Res       Date:  2014-06-19       Impact factor: 12.531

9.  Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells.

Authors:  Grazyna Nowak
Journal:  J Biol Chem       Date:  2002-09-05       Impact factor: 5.157

10.  Klotho has dual protective effects on cisplatin-induced acute kidney injury.

Authors:  Monica C Panesso; Mingjun Shi; Han J Cho; Jean Paek; Jianfeng Ye; Orson W Moe; Ming Chang Hu
Journal:  Kidney Int       Date:  2013-12-04       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.